Global Product Pipeline
Building the best product pipeline in the industry
- The Pathfinders Fund
- Excellence in Pharmaceutical Research and Education
- Collaborative Innovative Research Fund (CIRF)
A Canadian R&D Leader
GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. With more than $176 million invested in research and development in 2006 alone, GSK is one of the top 15 contributors to R&D in Canada, across all industries. Globally, the company spends $5 billion every year on R&D.
Clinical Studies
In 2006, GlaxoSmithKline invested close to $60 million in clinical trials in Canada, conducting more than 50 trials and enrolling well over 2,000 patients worldwide clinical trials program.
- The company conducted more than 60 academic research proposals in 2006 with physicians across Canada.
- The Clinical Development Group typically works on more than 35 different chemical compounds in clinical development in Canada, varying from phase I to phase IV trials.
Pharmaceutical Development
The company's Pharmaceutical Development Division has developed a number of products including: Zofran® syrup and the fast-disintegrating Zofran® ODT tablets for nausea and vomiting associated with chemotherapy and radiotherapy treatments; and Heptovir® tablets for the treatment of hepatitis B.
The Pathfinders Fund
GlaxoSmithKline's $22 million Pathfinders Fund for Leaders in Canadian Health Science Research was established to help Canada become a world leader in R&D. This initiative encourages health science research and fosters medical innovation in Canadian medical schools.
Your Health
Caring about your health
Understanding how diseases develop and the treatments that are available are important steps in staying healthy.